Prakt. Lékáren. 2018; 14(1e) [Neurol. praxi. 2017;18(3):179-185]

New perspectives of the treatment of migraine

MUDr. Rudolf Kotas, Ph.D.
Neurologická klinika LF UK a FN Plzeň

The acute treatment of migraine attacks is so far limited to the use of simple analgesics, non-steroidal anti-inflammatory drugs, ergotaminesand triptans. On the basis of our knowledge about pathophysiology of migraine, which is mentioned in this article, new medicaments for thetreatment of acute migraine attacks have been developed targeted especially to calcitonin gene–related peptide (CGRP) and serotonin 5-HT1Freceptors. Other therapeutic targets are mentioned, such as glutamate, combination of 5-HT1B/1D receptors and neuronal nitric oxide synthesisand medicament influencing cortical spreading depression. In the prophylaxis of migraine, the most promising new approach are humanizedantibodies against CGRP or the CGRP receptor. Non – invasive and invasive neuromodulation techniques are being developed at present inthe acute and prophylactic treatment.

Keywords: calcitonin gene-related peptid (CGRP), serotonin 5-HT1F receptors, nitric oxide, glutamate, cortical spreading depression, monoclonal
antibodies against CGRP or CGRP receptors, anticonvulsant drugs

Published: March 24, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotas R. New perspectives of the treatment of migraine. Praktické lékárenství. 2018;14(E-verze 1/18):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cady R K, Mathew N, Diener H Ch, Hu P, Haas M, Novak GP. On behalf of the study Group. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009; 49(2): 216-226. Go to original source... Go to PubMed...
    2. Diener H Ch, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015; 14(10): 1010-1022. Go to original source... Go to PubMed...
    3. Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol 2014; 13(9): 885-892. Go to original source... Go to PubMed...
    4. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine. A randomized, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014; 13(11): 1100-1107. Go to original source... Go to PubMed...
    5. Ferrari M, Farkkila M, Reuter U, Pilgrim A, Davis Ch, Krauss M, Diener H Ch. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - a randomized proof-of-concept trial. Cephalalgia 2010; 30(10): 1170-1178. Go to original source... Go to PubMed...
    6. Ferrari MD, Farkkila M, Géraud G, and the COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomized, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11(5): 405-413. Go to original source... Go to PubMed...
    7. Goadsby PJ. Pathophysiology of migraine. Neurol Clin 2009; 27(2): 335-360. Go to original source... Go to PubMed...
    8. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid Ch, Lines Ch, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcium gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet 2008; 372(9656): 2115-2123. Go to original source... Go to PubMed...
    9. Ho TW, Connor KM, Yhang Y, Pearlman E, Koppenhaver J, Fan X, Lines Ch, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014; 83(11): 958-966. Go to original source... Go to PubMed...
    10. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HCH. Ketamine can stop aura in hemiplegic migraine. Cephalalgia 2000; 20(4): 268-270.
    11. Kotas R. Současný pohled na patofyziologii migrény. Cesk Slov Neurol N 2011; 74/107(6): 654-661.
    12. Kotas R. Bolesti hlavy v klinické praxi. Praha: Maxdorf, 2015: 312s.
    13. Lenz R, Silberstein S, Dodick D, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Sun H. Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG334 for the prevention of episodic migraine. Cephalalgia 2015; 35(Suppl 6): 5.
    14. Medve R, Andrews J. Effects of fixed dose combination of nNOS inhibition and 5-HT agonism on progression of migraine with and without aura. Cephalalgia 2009; 29(1): 126.
    15. Olesen J, Diener H Ch, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist bibn4096bs for the acute treatment of migraine. N Engl J Med 2004; 350(11): 1104-1110. Go to original source... Go to PubMed...
    16. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003; 4(5): 386-398. Go to original source... Go to PubMed...
    17. Sadeghian H. Motiei-Langroudi R, Ghabaee M. Comparison of levetiracetam and sodium valproate in migraine prophylaxis: a randomized placebo-controlled study (abstract). 56th Annual Scientific Meeting, American Headache Society, June 26-29, 2014, Los Angeles, USA.
    18. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Rhebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F. LY293558, a novel AMPA, GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004; 24(7): 596-602. Go to original source... Go to PubMed...
    19. Silberstein SD, Schoenen J, Gobel H, Diener H Ch, Elkind AH, Klapper JA, Howard RA. Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine. Cephalagia 2009; 29(Suppl. 2): 17-27. Go to original source... Go to PubMed...
    20. Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observatiobnal study. Headache 2011; 51: 287-291. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.